20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.
Dr Simon Stott appointed Director of Research
Cure Parkinson’s is pleased to announce that Dr Simon Stott has been promoted to the role of Director of Research.
A million steps forward for Parkinson’s
On Tuesday 31 May, six friends from Hertfordshire crossed the finish line of their challenge of collectively walking a million steps in May, raising funds and awareness for Parkinson’s research.
2025 Manchester Marathon
The adidas Manchester Marathon is one of the UK’s premier running events, famous for its fast, flat and friendly route. Why not take on this popular race for Cure Parkinson’s? The event prides itself on welcoming all to take on the 26.2 mile challenge, from...
The 2022 Parkinson’s drug development pipeline report
The 2022 annual report, outlining the current development pipeline of new drug-based treatments for Parkinson’s, has been published.